GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Current Deferred Revenue

Nuvation Bio (Nuvation Bio) Current Deferred Revenue : $0.00 Mil (As of Sep. 2021)


View and export this data going back to 2020. Start your Free Trial

What is Nuvation Bio Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Nuvation Bio's current deferred revenue for the quarter that ended in Sep. 2021 was $0.00 Mil.

Nuvation Bio Current Deferred Revenue Historical Data

The historical data trend for Nuvation Bio's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Current Deferred Revenue Chart

Nuvation Bio Annual Data
Trend Dec20 Dec21
Current Deferred Revenue
- -

Nuvation Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Current Deferred Revenue Get a 7-Day Free Trial - - - - -

Nuvation Bio Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuvation Bio (Nuvation Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
1500 Broadway, Suite 1401, New York, NY, USA, 10036
Nuvation Bio Inc is a biopharmaceutical company. The company is engaged in developing therapeutic candidates for the unmet needs in oncology. The firm operates in pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates as treatments for cancer patients.